US FDA panel to review Forest's Bystolic for heart failure
This article was originally published in Scrip
Executive Summary
The US FDA's cardiovascular and renal drugs advisory panel will convene on January 11th to consider a chronic heart failure indication for Forest Laboratories' beta blocker Bystolic (nebivolol, licensed from Mylan).